Exceptional Response To Everolimus in Bladder Cancer Patient With Rare Genetic Mutations
Complete response for 14 months to the drug everolimus and pazopanib was experienced by a patient wit bladder cancer, in a phase I trial.
Complete response for 14 months to the drug everolimus and pazopanib was experienced by a patient wit bladder cancer, in a phase I trial.
The study may also provide insight into the pathways of bladder cancer.
Jan Nolta, professor and director of the UC Davis Stem Cell program said that the study may provide important data for basic research in determining the deviations from normal biological processes that trigger malignancies in developing bladder cells.
Bladder Cancer Survival Rates in UK Get Worse!
Of the top 10 cancers affecting people living in the UK, the survival rates associated with bladder cancer are found to get worse
Of the top 10 cancers affecting people living in the UK, the survival rates associated with bladder cancer are found to get worse
Source-ANI
Bladder Cancer Study Reveals Potential Drug Targets
Investigators have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.
Investigators have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.
